ESC Professional Premium Access

Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents

Congress Presentation

About the speaker

Doctor Marios Sagris

Hippokration General Hospital, Athens (Greece)
0 follower

5 more presentations in this session

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Speaker: Doctor A. Shiraki (Saga, JP)


Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.

Speaker: Mrs P. Nikolaou (Athens, GR)


Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.

Speaker: Doctor I. Ikonomidis (Athens, GR)


Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

Speaker: Mr G. Wolff (Duesseldorf, DE)


Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Speaker: Doctor M. Elmegaard (Copenhagen, DK) Doctor A. Falkentoft (Roskilde, DK)


Access the full session

Anti-diabetic pharmacotherapy in clinical practice

Speakers: Doctor M. Sagris, Doctor A. Shiraki, Mrs P. Nikolaou, Doctor I. Ikonomidis, Mr G. Wolff...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb